Naloxone in chronic schizophrenic patients: Neuroendocrine and behavioral effects

Joel E. Kleinman, Daniel R. Weinberger, Alan Rogol, David J. Shiling, Wallace B. Mendelson, Glenn C. Davis, William E. Bunney, Richard Jed Wyatt

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Naloxone produced improvement in abnormal thought content in medicated chronic schizophrenic patients, but not in drug-free patients. In contrast, drowsiness and increases in plasma prolactin concentrations were seen only in drug-free schizophrenic patients. Although growth hormone concentrations increased in drug-free and medicated schizophrenic patients, the time course was different in the two groups. Neuroleptics appear to alter naloxone's clinical and neuroendocrine effects in chronic schizophrenic patients.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalPsychiatry research
Issue number1
StatePublished - Aug 1982
Externally publishedYes


  • Naloxone
  • growth hormone
  • neuroleptics
  • prolactin
  • schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Naloxone in chronic schizophrenic patients: Neuroendocrine and behavioral effects'. Together they form a unique fingerprint.

Cite this